Project Grant R43AI134200

Federal Project Grant Award Summary Loyola University of Chicago's Health Sciences Campus received a $781,718 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective June 1, 2025 through May 31, 2030. The award supports the development of a novel T cell-based vaccine designed to prevent dengue virus (DENV) and Zika virus (ZIKV) infection while avoiding antibody-dependent enhancement...

Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Research Foundation For The State University Of New York at the University at Albany a Project Grant of $227,115 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support scientific investigation into the molecular mechanisms of Zika virus (ZIKV). The award, issued on February 3, 2026, with a completion date of January 31, 2028, funds research examining...

The Flavivirus and Alphavirus REVAMPP (FLARE) Center, funded by a $46,715,173 Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), is developing and optimizing protein nanoparticle, virion-based, and mRNA vaccine platforms, as well as monoclonal antibody-based treatments to rapidly respond to emerging flaviviruses and alphaviruses with pandemic potential. The Center integrates the work of multiple...

Cooperative Agreement Summary Boston Children's Hospital, in partnership with the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), received a cooperative agreement award of $1.67 million on September 25, 2025, to conduct a Phase 1 clinical study evaluating a novel messenger RNA (mRNA)-lipid nanoparticle (LNP)-based SARS-CoV-2 vaccine incorporating controlled biodistribution technology and interleukin-12...

Federal Grant Award Summary Synvect, Inc. received a $605,074 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 1, 2025, with completion targeted for February 28, 2026. The award supports the finalization of development and commercialization of NextGenSIT, an innovative genetic engineering technology for biological control of Aedes aegypti mosquitoes—the primary vector...

Grant Award Summary Duke University received a $791,661 Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025, through July 31, 2030. The award supports research focused on developing an HIV-1 vaccine utilizing integrase-defective lentiviral vectors (IDLVs) to deliver HIV and SIV antigens. The research aims to optimize vaccine delivery platforms and multi-antigen strategies...

Federal Project Grant Award Summary L2 Diagnostics LLC received a $299,954 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 15, 2025, through August 31, 2027. The award supports a Phase I feasibility Small Business Technology Transfer (STTR) project focused on developing PFAG, a novel multivalent peptide vaccine candidate against malaria. The primary deliverables...

Federal Grant Award Summary Advanced Virology Inc. received a $279,270 Project Grant award from the Centers for Disease Control and Prevention (CDC), Office of the Director, under the CDC Investigations and Technical Assistance program (CFDA 93.283) for the period of September 30, 2025, through September 29, 2026. The award supports the development of low-cost and high-efficiency DNA-based reverse genetics platforms designed for manufacturing RNA virus products. This initiative aligns with the...

This Project Grant award from the National Institute of Allergy and Infectious Diseases supports the development of a novel plant-based source for squalene as a natural vaccine adjuvant. The $514,006 award to Synshark LLC supports research to engineer tobacco plants to stably produce and accumulate squalene on their leaves. This work directly relates to the commercialization plan to provide a non-animal, indoor grown natural adjuvant for vaccines. Currently, squalene used in vaccines is...

Federal Grant Award Summary Arizona State University received a $431,750 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025 through July 31, 2027. The grant funds research to develop and evaluate a safer, more effective vaccine against mpox (monkeypox virus). The research leverages recent findings demonstrating that mpoxvirus exhibits unique sensitivity to...